Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics

about

Emerging pharmaceutical therapies for COPD.Drugs and Targets in Fibrosis.Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases.

P2860

Q38645203-EDE9332A-7A7D-4762-A732-E6B6BAFED159 Q47119118-9347C4D9-4BF6-4B27-99AE-8033F3C49FFB Q47921833-038F0C4C-ABCA-406C-B4A7-9BB430E4EF6F

P2860

Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics

Item

http://www.wikidata.org/entity/Q38128288

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Vasoactive intestinal Peptide ...... le in respiratory therapeutics

@en

type

Item

label

Vasoactive intestinal Peptide ...... le in respiratory therapeutics

@en

prefLabel

Vasoactive intestinal Peptide ...... le in respiratory therapeutics

@en

P1476

Vasoactive intestinal Peptide ...... le in respiratory therapeutics

@en

P2093

Ag Mathioudakis

http://www.w3.org/2001/XMLSchema#string

E Evangelopoulou

http://www.w3.org/2001/XMLSchema#string

Ga Mathioudakis

http://www.w3.org/2001/XMLSchema#string

V Chatzimavridou-Grigoriadou

http://www.w3.org/2001/XMLSchema#string

P2860

VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins

Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration.

Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide.

Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels.

Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.

Regulation of apoptosis by vasoactive peptides.

Vasoactive intestinal polypeptide as mediator of asthma.

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension.

Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma.

P304

12-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23935337

http://www.w3.org/2001/XMLSchema#string

P932

3738270

http://www.w3.org/2001/XMLSchema#string

Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics

about

P2860

P2860

Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932